HilleVax (HLVX)
(Delayed Data from NSDQ)
$1.89 USD
-0.02 (-1.05%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $1.89 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.89 USD
-0.02 (-1.05%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $1.89 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
Zacks News
After Plunging -86.93% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax (HLVX)
by Zacks Equity Research
The heavy selling pressure might have exhausted for HilleVax (HLVX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down -88.84% in 4 Weeks, Here's Why HilleVax (HLVX) Looks Ripe for a Turnaround
by Zacks Equity Research
HilleVax (HLVX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
by Zacks Equity Research
IDEAYA Biosciences (IDYA) and uniQure N.V. (QURE) are in the spotlight following positive pipeline updates.
HilleVax (HLVX) Tanks as Norovirus Vaccine Study in Infants Fails
by Zacks Equity Research
HilleVax's (HLVX) phase IIb NEST-IN1 study evaluating HIL-214 for preventing acute gastroenteritis caused by norovirus infection in infants fails to meet its primary efficacy endpoint. Stock falls.
Wall Street Analysts Believe HilleVax, Inc. (HLVX) Could Rally 92.19%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for HilleVax, Inc. (HLVX) points to a 92.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
HilleVax, Inc. (HLVX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
HilleVax, Inc. (HLVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does HilleVax, Inc. (HLVX) Have the Potential to Rally 107.23% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for HilleVax, Inc. (HLVX) points to a 107.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Predict a 56.76% Upside in HilleVax, Inc. (HLVX): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 56.8% in HilleVax, Inc. (HLVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
How Much Upside is Left in HilleVax, Inc. (HLVX)? Wall Street Analysts Think 87.76%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 87.8% in HilleVax, Inc. (HLVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
After Plunging 32.4% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax, Inc. (HLVX)
by Zacks Equity Research
HilleVax, Inc. (HLVX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down 25.2% in 4 Weeks, Here's Why You Should You Buy the Dip in HilleVax, Inc. (HLVX)
by Zacks Equity Research
HilleVax, Inc. (HLVX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why "Trend" Investors Would Love Betting on HilleVax, Inc. (HLVX)
by Zacks Equity Research
HilleVax, Inc. (HLVX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Wall Street Analysts Predict a 67% Upside in HilleVax, Inc. (HLVX): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 67% in HilleVax, Inc. (HLVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.